Cleveland BioLabs, Inc. (Nasdaq: CBLI) is a clinical-stage biotechnology company with a focus on oncology development. It specializes in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. The company was founded in 2003 and is headquartered in Buffalo, New York. It has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children’s Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs was founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. The following table shows key financial figures for the company for 2011, 2012 and 2013 (parenthesis represent negative figures).